Reported 18 days ago
Novo Nordisk's stock experienced a significant drop, reaching a 9-month low after disappointing guidance for 2025 overshadowed strong sales growth of its Wegovy weight-loss drug. Despite an 8% surge the previous day, analyst comments regarding the company's projected sales growth in 2025 contributed to the decline, with shares falling 3% in Copenhagen. The company's stock remains down nearly 30% from its June peak, prompting speculation about market dynamics and hedge fund strategies.
Source: YAHOO